Buda Juice Inc

Análisis de la acción Buda Juice Inc (BUDA)

$6.550

-0.069 (-1.06%)Al cierre

Loading chart…
Máximo
7.115
Apertura
7.115
Precio medio ponderado por volumen
6.65
Volumen
5.98K
Capitalización
—
Mínimo
6.300
Importe
39.81K
EV/EBITDA, TTM
27.16

Buda Juice, Inc. operates in a beverage industry, focused on UltraFresh juice-offering cold-crafted citrus-based drinks. The Company offers an end-to-end cold chain platform that always delivers cold, freshly crafted juice, lemonades and wellness shots to grocery retailers in Texas. Its product portfolio consists of fresh citrus juice, a fresh citrus-based line of lemonades and wellness shot offerings across multiple brand lines and retail customers, all produced using its cold chain process. Its products include Buda Juice (Organic), Buda Fresh - Value-Forward Offering (Non-Organic), and Private Label Products (Non-organic and Organic). Buda Fresh includes Fresh 12 oz Lime Juice, 16 oz and 128 oz Lemon Juice, Fresh Orange and Grapefruit Juice (16 oz, 32 oz and 52 oz), and Fresh Citrus-based Lemonades and Limeades (16 oz and 52 oz). Private Label Products include Fresh Citrus Line (52 oz) and Fresh Citrus-based Lemonades and Limeades (52 oz).

www.budajuice.com

Análisis de IA of Buda Juice Inc (BUDA)

Comprar

Buda Juice appears to be a strong buy at the current price of $7.22, especially with an RSI of 62.22 indicating bullish momentum. The stock has a significant upside potential with an analyst price target of $12, suggesting a potential gain of 66.67%. Additionally, the company has shown robust revenue growth, with Q2 2026 revenue reaching $4.5 million, a substantial increase compared to previous quarters. However, investors should be cautious of the forward P/E ratio of 49.02, which indicates that the stock may be overvalued if growth does not meet expectations.

Métricas de valoración

El PER previsto actual de Buda Juice Inc (BUDA) es 49.26, frente a su media de 5 años de 48.93.

PER previsto

Valor razonable
Media 5A P/E
48.93
P/E actual
49.26
Sobrevalorada
50.18
Infravalorada
47.68

EV/EBITDA previsto

Valor razonable
Media 5A EV/EBITDA
49.93
EV/EBITDA actual
27.16
Sobrevalorada
179.76
Infravalorada
-79.90

Precio/ventas previsto

Valor razonable
Media 5A P/S
170.84
P/S actual
4.00
Sobrevalorada
1138.27
Infravalorada
-796.59

Cronología de eventos

2026-08-13 (ET)

07:30:00

Buda Juice Reports Q2 Revenue of $4.5M

2026-05-26 (ET)

07:10:00

Buda Juice Dual Lists on NYSE Texas Effective May 26, 2026

2026-05-13 (ET)

07:10:00

Buda Juice Reports Q1 Adjusted EPS of 5 Cents, Revenue of $3.5M

2026-05-11 (ET)

07:00:00

Buda Juice Launches New Drink in 246 Walmart Stores

2026-03-26 (ET)

07:10:00

Buda Juice Reports FY25 Revenue of $12.6M

Noticias

Preguntas frecuentes sobre BUDA, respondidas por Alphio AI

Buda Juice, Inc. operates in a beverage industry, focused on UltraFresh juice-offering cold-crafted citrus-based drinks. The Company offers an end-to-end cold chain platform that always delivers cold, freshly crafted juice, lemonades and wellness shots to grocery retailers in Texas. Its product portfolio consists of fresh citrus juice, a fresh citrus-based line of lemonades and wellness shot offerings across multiple brand lines and retail customers, all produced using its cold chain process. Its products include Buda Juice (Organic), Buda Fresh - Value-Forward Offering (Non-Organic), and Private Label Products (Non-organic and Organic). Buda Fresh includes Fresh 12 oz Lime Juice, 16 oz and 128 oz Lemon Juice, Fresh Orange and Grapefruit Juice (16 oz, 32 oz and 52 oz), and Fresh Citrus-based Lemonades and Limeades (16 oz and 52 oz). Private Label Products include Fresh Citrus Line (52 oz) and Fresh Citrus-based Lemonades and Limeades (52 oz). It operates in the Consumer Non-Cyclicals sector.

Buda Juice appears to be a strong buy at the current price of $7.22, especially with an RSI of 62.22 indicating bullish momentum. The stock has a significant upside potential with an analyst price target of $12, suggesting a potential gain of 66.67%. Additionally, the company has shown robust revenue growth, with Q2 2026 revenue reaching $4.5 million, a substantial increase compared to previous quarters. However, investors should be cautious of the forward P/E ratio of 49.02, which indicates that the stock may be overvalued if growth does not meet expectations.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Artículos relacionados

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar